Amprius Technologies, Inc.
For the period ended Dec 31, 2025. Filed Mar 6, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 6, 2026
AMPX$9.17-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATEDS TATEMENTS OFCASHF LOWS
| Year ended December 31, | ||
|---|---|---|
| (In thousands) | 2025 | 2024 |
| Cash flows from operating activities: | ||
| Net loss | $(44,024) | $(44,671) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 7,410 | 7,343 |
| Depreciation and amortization | 4,366 | 3,808 |
| Amortization of deferred costs | — | 1,246 |
| Non-cash operating lease expense | 5,143 | 5,143 |
| Impairment and other | 22,524 | 1,862 |
| Other non-cash items | 454 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (18,609) | (4,315) |
| Inventories | (161) | (5,844) |
| Deferred costs | — | (467) |
| Prepaid expenses and other current assets | (3,846) | 533 |
| Other assets | 28 | (17) |
| Accounts payable | (998) | 5,884 |
| Accrued and other current liabilities | (1,170) | (747) |
| Deferred revenue | (1,538) | (1,796) |
| Deferred grant | 2,738 | — |
| Operating lease liabilities | (3,451) | (1,314) |
| Net cash used in operating activities | (31,134) | (33,352) |
| Cash flows from investing activities: | ||
| Purchase of property, plant and equipment | (4,400) | (3,207) |
| Net cash used in investing activities | (4,400) | (3,207) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in connection with the At Market Issuance Sales Agreement, net | 63,668 | 33,416 |
| Proceeds from issuance of common stock upon exercise of stock warrants | 2,301 | 14,384 |
| Payment of equity financing costs | — | (756) |
| Proceeds from exercise of stock options | 5,071 | 109 |
| Net cash provided by financing activities | 71,040 | 47,153 |
| Net increase in cash, cash equivalents and restricted cash equivalents | 35,506 | 10,594 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | 4 | — |
| Cash, cash equivalents and restricted cash equivalents, beginning of year | 56,411 | 45,817 |
| Cash, cash equivalents and restricted cash equivalents, end of year | $91,921 | $56,411 |
| Reconciliation of cash, cash equivalents and restricted cash equivalents shown on the consolidated balance sheets: | ||
| Cash and cash equivalents | $90,465 | $55,155 |
| Restricted cash equivalents included in prepaid expenses and other current assets | 200 | — |
| Restricted cash equivalents included in other assets | 1,256 | 1,256 |
| Total cash, cash equivalents and restricted cash equivalents | $91,921 | $56,411 |
| Supplemental non-cash investing and financing activities: | ||
| Unpaid purchases of property, plant and equipment | $322 | $48 |
| Increase in fair value of modified stock warrants | $— | $727 |
| Cancellation and retirement of common stock | $— | $1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.